secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001213900-24-069662
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma sells legacy Gencaro and rNAPc2 assets to Genvara for $300K
--------------------------------------------------------------------------

- ARCA entered Asset Purchase Agreement with Genvara Biopharma to sell all rights in Gencaro (bucindolol) for atrial fibrillation and rNAPc2 (AB201) for COVID-19.
- Total cash consideration is $300,000, payable pre-closing and held in escrow until the Closing.
- Closing of asset sale is automatic immediately following the First Merger (Oruka merger).
- Buyer Genvara is controlled by Dr. Michael Bristow, ARCA's former President/CEO.
- The asset sale is a condition to the broader reverse merger with Oruka Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390024069662/0001213900-24-069662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390024069662/ea0211472-8k425_arcabio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-069662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer